Subcutaneous Administration of Otelixizumab is Limited by Injection Site Reactions: Results of an Exploratory Study in Type 1 Diabetes Mellitus Patients
2016 ◽
Vol 124
(05)
◽
pp. 288-293
◽
Keyword(s):
2011 ◽
Vol 31
(3)
◽
pp. 174-179
◽
Keyword(s):
1994 ◽
Vol 11
(8)
◽
pp. 802-805
◽
2011 ◽
Vol 2011
◽
pp. 217-219
Keyword(s):